Photo from wikipedia
Key Points Question What is the overall survival benefit of cancer drugs approved in China between 2005 and 2020? Findings In this mixed-methods study comprising a systematic review and cross-sectional… Click to show full abstract
Key Points Question What is the overall survival benefit of cancer drugs approved in China between 2005 and 2020? Findings In this mixed-methods study comprising a systematic review and cross-sectional analysis of 78 cancer drugs for 141 indications, 68 new cancer drug indications approved by Chinese authorities between 2005 and 2020 had documented evidence of overall survival benefit, and 34 did not prolong life. Meaning Given regulatory reforms in recent years, these findings highlight the need to routinely monitor the clinical benefits of new cancer therapies in China.
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!